NEWS RELEASE

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

2026-11-17

Recognition is part of the Digital Health Hub Foundation Digital Health & AI Awards, which received more than 1,300 submissions globally

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the impact of Natera's Signatera™ molecular residual disease (MRD) test on cancer care.

The winners were announced live at the 2026 HLTH Conference in Las Vegas. This year's competition drew more than 1,300 submissions worldwide, recognizing innovations advancing healthcare across multiple categories. The Cancer, Screening & Early Detection category was introduced for the first time this year, reflecting the growing role of digital and data-driven tools in the cancer continuum.

Signatera is a personalized MRD and monitoring test for patients diagnosed with cancer, designed to the unique genomic signature of each patient's tumor. Signatera detects and quantifies tiny fragments of circulating tumor DNA (ctDNA) in the blood, providing an early signal of disease recurrence and therapy response across cancer types. It is the most widely adopted and extensively validated MRD test, used by the majority of oncologists in the U.S.

"Signatera is transforming the practice of medicine by enabling earlier, more targeted interventions for those patients who need them, and by helping spare others from unnecessary treatment and its side effects," said Solomon Moshkevich, Chief Executive Officer, Natera. "We are honored by this recognition from HLTH 2026, and we

are grateful to the patients, clinicians, researchers, and partners who make our work possible."

About Natera

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 475 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit **www.natera.com**.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at **www.natera.com/investors** and **www.sec.gov**.

Investor Relations: Mike Brophy, CFO, Natera, Inc., **investor@natera.com**
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., **pr@natera.com**

Source: Natera, Inc.